Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | CMO & Head of Late-Stage Dev. | July 16, 2026 | July 20, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 21, 2022 | June 23, 2022 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,118 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Sale · Disposed 1,877 · Balance 21,118 |
| Common StockSEC Table I · non-derivative | Direct | 30,916 |
Reported balance
After 2026-07-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 9,798 · Balance 30,916 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-07-16 | Direct | 24,496 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Grant · Acquired 24,496 · Balance 24,496 F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.65 · Expires 2036-07-15 | Direct | 42,298 |
Reported balance
After 2026-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-16 · Grant · Acquired 42,298 · Balance 42,298 F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Kura Oncology, Inc.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.84 · Expires 2032-06-20 | Direct | 23,000 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 23,000 · Balance 23,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 54,000 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 54,000 · Balance 54,000 F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theseus Pharmaceuticals, Inc.
Report date February 14, 2024 · Filed February 14, 2024
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 269 | $107.79 | $28,995.51 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,272 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $106.47 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · derivative · entry 13 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2030-07-01 F9 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,474 | $106.47 | $156,936.78 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,541 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,015 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001209191-20-039071 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:23 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038174 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,354 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on June 18, 2020. The performance shares will vest in full on June 28, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Each performance share initially represented the right to receive one share of common stock based on, and subject to, the approval of a new chemical entity developed by the issuer as a drug by the U.S. FDA or the European Medicines Agency during a specified performance period. F2 · balance_after: Includes an aggregate of 95,832 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units and performance shares that have not vested as of June 18, 2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:44 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010197 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,354 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 13, 2020. The performance shares vest 25% annually over four years from the grant date of July 2, 2019, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded, and the performance criteria was achieved at the 101.80% level. F2 · balance_after: Including the Performance Stock Units earned on February 13, 2020, this includes an aggregate of 70,832 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:20 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004466 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054618 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,473 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on October 30, 2019. The performance shares vest 100% on the third anniversary of the grant date of June 28, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical milestones determined by the Issuer's Compensation Committee in October 2019 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 100% of the number of performance shares awarded, and the performance criteria was achieved at the 100% level. F2 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 20:45 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 409 | $81.39 | $33,288.51 |
DisclosureSEC source: 0001209191-19-042176 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,473 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:43 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 267 | $85.28 | $22,769.76 |
DisclosureSEC source: 0001209191-19-041573 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,882 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 417 | $85.01 | $35,449.17 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,149 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040919 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,566 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $19.55 | $0.00 |
DisclosureSEC source: 0001209191-19-039244 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common stock · 13,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 8,357 | $87.96 | $735,081.72 |
DisclosureSEC source: 0001209191-19-039000 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,805 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $87.23 - $89.01. F4 · balance_after: Includes an aggregate of 10,805 shares of common stock issuable pursuant to previously reported earned performance stock units and restricted stock units that have not vested. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:34 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 5,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011238 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,162 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2019. The performance shares vest 25% annually over four years from the grant date of July 2, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2018 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 150% of the number of performance shares awarded, and the performance criteria was achieved at the 83% level. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units that have not vested as of February 14, 2019. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 847 | $74.21 | $62,855.87 |
DisclosureSEC source: 0001209191-19-002792 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,773 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:32 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002792 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F3 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:06 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 577 | $70.19 | $40,499.63 |
DisclosureSEC source: 0001209191-18-043106 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,620 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:45 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 262 | $68.28 | $17,889.36 |
DisclosureSEC source: 0001209191-18-041685 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,197 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:45 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041685 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:11 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $16.35 | $0.00 |
DisclosureSEC source: 0001209191-18-036662 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:30 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,081 | $86.61 | $180,235.41 |
DisclosureSEC source: 0001209191-18-017263 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,459 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:45 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,167 | $0.00 Strike: $95.34 | $0.00 |
DisclosureSEC source: 0001209191-18-005400 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,167 Underlying: Common Stock · 21,167 shares Expires 2028-01-23 F2 · derivative.exercise_date: Beginning January 24, 2018, options become exercisable in full on January 24, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:45 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $94.63 | $0.00 |
DisclosureSEC source: 0001209191-18-005400 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:31 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 625 | $123.15 | $76,968.75 |
DisclosureSEC source: 0001209191-17-052984 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,540 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 16,777 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 397 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 9 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,326 Underlying: Common Stock · 397 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,192 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,495 Underlying: Common Stock · 1,192 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 522 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,348 Underlying: Common Stock · 522 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 397 | $125.00 | $49,625.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 16,777 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,192 | $125.00 | $149,000.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 522 | $125.00 | $65,250.00 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,754 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 397 | $83.83 | $33,280.51 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,192 | $88.68 | $105,706.56 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 20:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 522 | $95.76 | $49,986.72 |
DisclosureSEC source: 0001209191-17-050884 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 522 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 9 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,870 Underlying: Common Stock · 522 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,772 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 Underlying: Common Stock · 4,772 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,191 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,687 Underlying: Common Stock · 1,191 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 522 | $131.09 | $68,428.98 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: This includes an 18,165 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 4,772 | $131.09 | $625,561.48 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,191 | $131.09 | $156,128.19 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $129.57 - $132.10. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 522 | $95.76 | $49,986.72 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 4,772 | $83.83 | $400,036.76 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 20:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,191 | $88.68 | $105,617.88 |
DisclosureSEC source: 0001209191-17-045911 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:39 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044394 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:39 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044394 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Stein's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 14,648 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:29 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,013 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-17-041385 · doc4.xml · derivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,878 Underlying: Common Stock · 6,013 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:29 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,870 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001209191-17-041385 · doc4.xml · derivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,392 Underlying: Common Stock · 3,870 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:29 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 6,013 | $125.00 | $751,625.00 |
DisclosureSEC source: 0001209191-17-041385 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,648 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an 14,648 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.